Twist bioscience Released with a quarterly loss of $ 0.66 per share against the estimate of the ZACKS consensus of a loss of $ 0.56. This is compared to a loss of $ 0.79 per share a year ago. These figures are adjusted for non -recurring items.
This quarterly report represents a profit surprise of -17.86%. There is a quarter, it was planned that this synthetic DNA manufacturer for the biotechnology industry has a loss of $ 0.62 per share when he really produced a loss of $ 0.53, which allowed a surprise of 14.52%.
During the last four quarters, the company has twice exceeded the consensual EPS estimates.
Twist Bioscience, which belongs to the Zacks Medical – Biomedical and Genetics industry, has recorded income of $ 92.79 million for the closed quarter March 2025, exceeding the consensual estimate of Zaks of 0.95%. This is compared to the income of $ 75.3 million of the year there is. The company has exceeded estimates of consensual income four times in the last four quarters.
The sustainability of the Immediate price movement of the action based on recently published figures and expectations of future profits will mainly depend on the commentary on management on the call for profits.
Twist bioscience stocks have lost approximately 15.6% since the start of the year compared to the drop in S&P 500 -3.3%.
What is the next step for Twist Bioscience?
While Twist Bioscience has underreaved the market so far this year, the question that comes to the minds of investors is: what is the next step for the stock?
There are no easy answers to this key question, but a reliable measure that can help investors solve this problem is the prospects for the benefit of the company. Not only does this include current expectations of consensual profits for the coming quarters, but also how these expectations have changed lately.
Empirical research shows a strong correlation between the movements of short -term actions and the trends in the revisions to estimate profits. Investors can follow these revisions by themselves or rely on a proven rating tool such as Rang Zacks, which has an impressive history of exploiting the power of profits revisions.
Before this version of the profits, the trend in estimation revisions for twist bioscience: unfavorable. Although the magnitude and management of estimation revisions can change by following the report on the profits that have just been published on the company, the current status is reflected in a Rank # 4 of Zacks (SELL) for the action. Thus, actions should underperform the market in the near future.
It will be interesting to see how estimates from the next quarters and the current year are changing in the coming days. The current estimate of BPA Consensus is – $ 0.56 out of $ 94.77 million in income for the coming quarter and – $ 2.14 out of $ 374.42 million in income for the current financial year.
Investors should be aware of the fact that industry prospects can also have a significant impact on action performance. Regarding the rank of the Zacks industry, Medical – Biomedical and Genetics is currently one of 34% of the 250 more Zacks Industries. Our research shows that the highest 50% of Zacks classified industries surpass the lowest 50% by a factor of more than 2 to 1.
Prime Medicine, Inc., another stock of the same industry, has not yet reported the results for the closed quarter March 2025.
This company should display a quarterly loss of $ 0.32 per share in its next report, which represents a variation from one year to the next of + 27.3%. The estimate of the CEPS of the consensus for the quarter has remained unchanged in the last 30 days.
Prime Medicine, Inc. income should be $ 4.58 million, up 676.3% compared to the quarter of the previous year.
Do you want the latest recommendations from Zacks Investment Research? Download 7 best actions for the next 30 days. What is
